Rapport Therapeutics
Logotype for Rapport Therapeutics Inc

Rapport Therapeutics (RAPP) investor relations material

Rapport Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Rapport Therapeutics Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

Pipeline and strategic positioning

  • RAP-219 achieved proof of concept in focal onset seizures in 2025 and bipolar mania in 2026; ~$814M in cash is expected to fund development through 2029.

  • FOCUS 1 and FOCUS 2 Phase III trials are enrolling; a Phase III program in primary generalized tonic-clonic seizures is planned for H1 2027.

  • RAP-219 bipolar mania Phase III is planned for H2 2027, following a Q1 2027 FDA End-of-Phase II meeting; two parallel studies are planned.

  • RAP-641, an α6β4 nicotinic program for migraine and neuropathic pain, is targeted to enter Phase I in 2027, with results expected in H2 2027.

Focal onset seizures

  • Phase II enrolled refractory focal onset seizure patients with RNS devices, enabling continuous EEG assessment alongside clinical seizure tracking.

  • RAP-219 reduced electrographic seizures by ~71% and clinical seizures by 78%; 24% of patients achieved seizure freedom.

  • Treatment was well tolerated; the most common adverse events were mild to moderate dizziness, headache and fatigue.

  • Phase III studies are powered conservatively, consistent with recent programs targeting a 30%–35% placebo-adjusted reduction in seizure frequency.

Bipolar mania

  • In a 21-day, placebo-controlled Phase II trial of 253 patients, RAP-219 showed a 3.1-point placebo-adjusted YMRS difference at week 3 and a 15.4-point absolute change in the treatment arm.

  • All 11 YMRS items improved; four were statistically significant. The secondary CGI scale showed a significant 0.4-point treatment difference versus placebo.

  • Adverse events were mild to moderate; AE-related withdrawal was 3.2% with RAP-219 versus 0.8% with placebo, while overall treatment discontinuations were not driven by AEs.

  • Phase III design may use 1.25 mg versus 0.75 mg in Phase II to achieve higher receptor occupancy earlier; global sites are under consideration to manage placebo response.

  • Phase III planning discussed three studies to secure at least two positive results; the design discussion cited 90% power, α=0.05 and a YMRS difference in the four-point range.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Rapport Therapeutics earnings date

Logotype for Rapport Therapeutics Inc
Q4 202610 Mar, 2027
Rapport Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Rapport Therapeutics earnings date

Logotype for Rapport Therapeutics Inc
Q4 202610 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Rapport Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small-molecule medicines targeting central nervous system disorders. The company's research focuses on understanding neuronal receptor biology to design precision treatments that address the complexities of neurological conditions. By mapping and targeting specific neuronal receptor complexes, Rapport aims to regulate receptor function and expression effectively. The company is headquartered in Boston, Massachusetts, and its shares are listed on NASDAQ.